Global rapid antibody test kit for COVID-19 market has gained momentum in recent years, and is estimated to have reached USD 1.64 billion in 2020, and is expected to touch USD 1.72 billion by 2026. On 30 January 2020, the World Health Organization (WHO) declared the COVID-19 (SARS-CoV-2) outbreak as a Public Health Emergency of International Concern (PHEIC) and shortly thereafter called for research on point of care diagnostics for use at the community level. In response to the growing COVID-19 pandemic and shortages of laboratory-based molecular testing capacity and reagents, multiple diagnostic test manufacturers have developed and begun selling rapid and easy-to-use devices to facilitate testing outside of laboratory settings.
These simple test kits are based either on detection of proteins from the COVID-19 virus in respiratory samples (e.g. sputum, throat swab) or detection, in blood or serum, of human antibodies generated in response to infection. The Rapid Test Kits approved by the US Food and Drug Administration are not meant for early diagnosis, but only to be used for surveillance and monitoring trends. The EU Medicine Agency’s guidelines, on par with the US Centers for Disease Control and Prevention (CDC), require that tests be 80% accurate on average. The major cause of the increasing patient rate is the high transmission rate among the population across the globe.

Global Rapid Antibody Test Kit for COVID-19 market overview Market Forecast and Trends

Growth Drivers

Increases cases of corona infected patients
The confirmed cases of corona infected patients are rising rapidly across the globe. More cases of Coronavirus disease are being expected across many regions of the world. Though, constant efforts at the individual, national, and international levels are being made to fight back against this pandemic. thus, the growth in the number of patients leads to high demand for rapid antigen test kits in the market. Rapid Diagnostic Tests (RDTs) are small, simple to use, stand-alone tests. They can be used by minimally trained staff, round the clock, and on single samples at the point of treatment, thus benefitting the whole market.

Rising Government Initiatives
The augmented factors for the growth of the rapid antibody test kit market include great government support. As the governments of different regions across the globe are trying their best to provide the facilities for fast detection of the infection. This would be helping in the prevention of the diseases from spreading. Hence, more and more rapid test kits are required in the market. Additionally, government initiatives of spreading awareness among the people, funding programs, and others have influenced the healthcare industry.
Recent Development

• Studies indicate that most patients produce an antibody response only after symptom onset during the second week. This means that COVID-19 infection diagnosis based on antibody response will often only be possible in the recovery phase when many of the opportunities for therapeutic intervention or disease transmission disruption have already passed. Antibody detection studies targeting COVID-19 can also cross-react with other pathogens, including other human coronaviruses, and result in false positives. Finally, whether RDTs detecting antibodies could predict whether an individual was resistant to COVID-19 virus reinfection, was examined.
• Blood samples were obtained from COVID-19 patients from various hospitals and from Chinese CDC laboratories to test the detection sensitivity and specificity of the combined antibody test COVID-19 IgG-IgM. At each site, the experiments were carried out separately. A total of 525 cases were tested: 397 (positive) clinically confirmed (including the PCR test) patients infected with SARS-CoV-2 and 128 patients who were not infected with SARS-CoV-2 (128 negatives).

Impact of COVID-19 in industry

The global economy and humanity have been pushed into a crisis due to the COVID-19 pandemic. Due to the high infection rate and adverse impact on public health systems, various governments have enforced nationwide lockdowns significantly impacting manufacturing supply chains, trade, and related services. Players are currently considering digital solutions that will enable them to serve the community and provide new opportunities to do business. The production, manufacturing, supply chain, and other operations, have slowed down globally aimed to limit the spread of the coronavirus.
On 30 January 2020, the World Health Organization (WHO) declared the COVID-19 (SARS-CoV-2) outbreak as a Public Health Emergency of International Concern (PHEIC) and shortly thereafter called for research on point of care diagnostics for use at the community level

Global Rapid Antibody Test Kit for COVID-19 market overview Market: By Antibody Type

Based on antibody type, the global rapid antibody test kits for Covid-19 are segmented into IgG and IgM. Amidst the segmentation, IgM is projected to dominate the global market with high potential. immunoglobulins are the key detection molecules in the immune system. The (IgM) antibody also known as the natural antibody is depicted as the µ heavy chain which is the largest chain. It is also generated as a B cell membrane-bound monomer and a secreted pentamer. Also, IgM is the first immunoglobulin that is developed during human fetal development. IgM is also the first antibody that responds during infection.

About Us
BlueWeave Consulting provides all kinds of Market Intelligence (MI) Solutions to businesses regarding various products and services online & offline. We offer comprehensive market research reports by analyzing both qualitative and quantitative data to boost up the performance of your business solution. BWC has built its reputation from the scratches by delivering quality inputs and nourishing long-lasting relationships with its clients.
More: https://www.blueweaveconsulting.com/press-release/global-rapid-antibody-test-kit